Does Sentara Cover Wegovy for Weight Loss? Plans, PA, and Costs

Whether Sentara covers Wegovy for weight loss depends entirely on which Sentara plan you carry. Some employer-sponsored commercial plans cover it when the employer opts in, Virginia Medicaid members on the Sentara Community Plan can get it as a non-preferred drug, and the Individual and Family marketplace plan, Medicare Advantage, SNP, and Medicaid-FAMIS plans exclude it for weight loss. Every covered plan also requires prior authorization with strict clinical criteria.1Sentara Health Plans. Sentara Health Plans Formulary – GLP-1 Weight Management Coverage

Coverage by Sentara Plan Type

Sentara’s formulary draws a hard line between plan categories for Wegovy prescribed for weight loss:

The same plan-by-plan pattern applies to Zepbound (tirzepatide) and Saxenda (liraglutide), the two other GLP-1 weight-loss medications Sentara includes in its weight management formulary.

Prior Authorization Criteria

Even on plans that cover Wegovy, you cannot fill a prescription without prior authorization. Sentara’s Pharmacy and Therapeutics Committee approved the current criteria in March 2026, and all conditions must be met.2Sentara Health Plans. Sentara Health Plans Pharmacy Prior Authorization – Weight Management Drugs

Initial Approval

To qualify for the first authorization, you must meet all of the following:

  • Age 12 or older. For ages 12 to 17, initial BMI must be at or above the 95th percentile for age and sex.
  • For adults, a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as hypertension, coronary artery disease, congestive heart failure, type 2 diabetes, dyslipidemia, or sleep apnea.
  • Participation in a weight-loss treatment plan during the previous six months, such as nutritional counseling, an exercise program, or a calorie- and fat-restricted diet, with an agreement to continue those efforts while on the medication.
  • No concurrent use of another GLP-1 receptor agonist such as Ozempic, Mounjaro, Trulicity, or Rybelsus.
  • Current height and weight documented in chart notes by the prescriber.

Initial authorization lasts seven months.2Sentara Health Plans. Sentara Health Plans Pharmacy Prior Authorization – Weight Management Drugs

Renewal

To continue past seven months, you must show at least a 5% decrease in body weight during the initial approval period. Subsequent renewals last up to 12 months and require you to maintain that 5% loss. You also need continued participation in a weight-loss treatment plan, provider attestation that you have not developed significant side effects, and confirmation of no medical or drug contraindications. Sentara will not renew authorization if your BMI drops below 18.5.2Sentara Health Plans. Sentara Health Plans Pharmacy Prior Authorization – Weight Management Drugs

What You’ll Pay When It’s Covered

Cost-sharing varies by employer group and plan design. On commercial plans that cover it, Wegovy is a Tier 3 (non-preferred brand) drug.1Sentara Health Plans. Sentara Health Plans Formulary – GLP-1 Weight Management Coverage As a reference point, the Sentara Vantage HMO plan offered to Virginia state employees for the 2026-2027 plan year charges a $45 copay for Tier 3 retail prescriptions up to a 30-day supply.3Virginia Department of Human Resource Management. Sentara Vantage HMO Plan Benefits Summary 2026 Another Sentara Vantage HMO document lists Tier 4 specialty drugs at 20% coinsurance capped at $300 per fill, though Wegovy’s Tier 3 classification suggests the lower copay tier would apply in most cases.4Old Dominion University. Sentara HMO Benefit Information Guide Check your plan’s benefit summary or call the number on your prescription ID card for the exact amount.

Medicaid members on the Sentara Community Plan pay no copay.1Sentara Health Plans. Sentara Health Plans Formulary – GLP-1 Weight Management Coverage

Commercial members can also apply Novo Nordisk’s Wegovy savings card, which reduces the copay to as little as $25 per month with a maximum savings of $100 per month. The card is not available to anyone on a government-funded plan such as Medicare, Medicaid, or TRICARE.5Novo Nordisk. Wegovy Savings Offer

A Workaround Through the Cardiovascular Indication

Wegovy has a second FDA-approved indication: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. On Sentara’s formulary, this indication has much broader coverage than the weight-loss one. Wegovy prescribed for cardiovascular risk reduction is on the formulary for Sentara Medicare Advantage plans (Tier 5), SNP plans, Medicaid, and Medicaid-FAMIS, in addition to the commercial plans. Only the Individual and Family Health Plan excludes Wegovy for both indications.1Sentara Health Plans. Sentara Health Plans Formulary – GLP-1 Weight Management Coverage

The clinical bar is higher. You must have documented cardiovascular disease, defined as a prior heart attack, prior stroke, or symptomatic peripheral arterial disease. The prescriber must be a cardiology, neurology, or vascular specialist, or must consult with one. You must be on guideline-directed cardiovascular therapy such as statins, beta-blockers, or ACE inhibitors, and you must be a non-smoker or on nicotine replacement therapy. A BMI of 27 or greater is still required.6Sentara Health Plans. Sentara Health Plans Pharmacy Prior Authorization – Wegovy Cardiovascular Event Risk Reduction

If your plan excludes weight-loss drugs but you have qualifying cardiovascular disease, this pathway can open coverage that would otherwise be unavailable.

Medicare Members and the GLP-1 Bridge Program

Sentara Medicare Advantage members have not been able to get Wegovy for weight loss through their plan. A new federal initiative is changing that. Beginning July 1, 2026, the Medicare GLP-1 Bridge Program lets Part D beneficiaries access Wegovy, Zepbound, and Foundayo at a fixed cost of $50 per month.7Medicare.gov. Weight Loss Drugs

The Bridge Program runs through CMS, not through individual Part D plans like Sentara. CMS manages the claims system and prior authorization directly. To qualify, you must be 18 or older and meet one of these BMI thresholds: 35 or higher with no additional conditions, 30 to 34.99 with specific comorbidities, or 27 to 29.99 with certain other risk factors. Beneficiaries who already receive GLP-1s through standard Part D, or who have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, are not eligible, because those conditions are usually covered under standard Part D benefits.8Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026

The $50 monthly copayment does not count toward Part D deductibles or out-of-pocket maximums, and Extra Help subsidies do not reduce it. Prior authorization through the Bridge Program is valid through December 31, 2027, as long as you do not switch medications.7Medicare.gov. Weight Loss Drugs

If Sentara Denies Coverage

A denial is not the end of the road. Start by identifying the reason. Denials usually fall into one of four buckets: the plan excludes weight-loss medications entirely, the prior authorization criteria were not met, documentation was incomplete, or step therapy requirements were not satisfied.

If the denial is based on clinical criteria or documentation, your prescriber can resubmit with additional evidence. A peer-to-peer review, where the prescriber speaks directly with Sentara’s medical reviewer, is available at the initial denial stage or during an appeal.9Novo Nordisk. Wegovy Denials and Appeals Guide A letter of medical necessity should include your BMI, weight history, documentation of prior weight-loss attempts, and any obesity-related comorbidities.

If the denial is a benefit exclusion—your plan simply does not cover weight-loss drugs—standard appeals have limited effectiveness. Two alternatives are worth considering. If you have established cardiovascular disease, your provider can submit a fresh prior authorization under the cardiovascular risk reduction indication, which is covered on more plan types.9Novo Nordisk. Wegovy Denials and Appeals Guide For employer-sponsored plans, Novo Nordisk provides a template letter you or your provider can send to the employer’s HR department asking that anti-obesity medications be added to the benefit plan.10Novo Nordisk. What to Pay for Wegovy

Appeals must typically be submitted within six months of the denial notice. If you are on a fully insured plan and exhaust internal appeals, external review by an independent reviewer may be available. For self-insured employer plans governed by ERISA, the appeals process follows the employer’s plan documents, and the plan must respond to a claim within 60 days.11Obesity Action Coalition. Appealing a Denial

If you want to pay out of pocket while you sort coverage out, Novo Nordisk sells Wegovy direct through NovoCare Pharmacy starting at $149 per month for certain doses, with introductory pricing for new patients on lower starter doses. Patients who are uninsured or whose plans exclude Wegovy may also qualify for Novo Nordisk’s Patient Assistance Program based on income.10Novo Nordisk. What to Pay for Wegovy